Bruker Corporation (BRKR)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Bruker Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 62.80 $ — 96% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 10.7% failed
- More than 10% revenue growth is expected for the coming year 4.2% failed
- Share count grows by less than 3% a year 0.5% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 2.5% failed
- Gross margin at 40% or higher and without meaningful erosion 45.9% failed
- Goodwill from acquisitions does not grow faster than revenue 24.8% failed
- Net debt below twice EBITDA 5.8 x EBITDA failed
- Operating cash flow covers the profits of the last three years 204 m passed
- Return on capital at 15% or higher, or up versus two years ago 4.8% failed
- Insiders hold at least 10% or are net buyers 27.0% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 4.9% below the current price.
- Consensus
- Sell
- Analyst Ratings
- 14
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.12 | 2.10 – 2.14 | 3,589 | 15.8% | 13 |
| 12/31/2027 | 2.43 | 2.32 – 2.62 | 3,742 | 14.6% | 13 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.38 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.09 | -93.60 | 980 | 14.60 | 1.40 | 190 | 153 |
| 2025: Q1 | 0.11 | -67.20 | 801 | 11.00 | 2.20 | 65 | 39 |
| 2025: Q2 | 0.05 | -2.40 | 797 | -0.40 | 1.00 | -128 | -149 |
| 2025: Q3 | -0.39 | -245.90 | 861 | -0.50 | -6.90 | -33 | -54 |
| 2025: Q4 | 0.17 | 89.20 | 977 | -0.20 | 2.70 | 230 | 207 |
| 2026: Q1 | 0.09 | -17.70 | 823 | 2.70 | 1.70 | 71 | 47 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,611 | 177 | 154 | 0.95 | 131 | 693 | 1,813 |
| 2017 | 1,766 | 215 | 79 | 0.49 | 154 | 734 | 1,949 |
| 2018 | 1,896 | 262 | 180 | 1.14 | 240 | 905 | 2,129 |
| 2019 | 2,073 | 301 | 197 | 1.26 | 213 | 907 | 2,772 |
| 2020 | 1,988 | 248 | 158 | 1.02 | 333 | 961 | 3,049 |
| 2021 | 2,418 | 413 | 277 | 1.81 | 282 | 1,071 | 3,650 |
| 2022 | 2,531 | 433 | 297 | 1.99 | 262 | 1,114 | 3,612 |
| 2023 | 2,965 | 437 | 427 | 2.90 | 350 | 1,377 | 4,250 |
| 2024 | 3,366 | 253 | 113 | 0.76 | 251 | 1,781 | 5,807 |
| 2025 | 3,437 | 236 | -9 | -0.06 | 134 | 2,457 | 6,241 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Bruker Corporation entwickelt, fertigt und vertreibt gemeinsam mit ihren Tochtergesellschaften wissenschaftliche Instrumente sowie Analyse- und Diagnostiklösungen. Sie ist in vier Segmenten tätig: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano und Bruker Energy & Supercon Technolog…
| Employees | 11,085 |
|---|---|
| Headquarters | Billerica, MA |
| Address | 40 Manning Road, 01821 Billerica, United States |
| Phone | 978 663 3660 |
| Website | bruker.com |
| IPO Date | 4. Aug 2000 |
| ISIN | US1167941087 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Frank H. Laukien Ph.D. | Chairman, CEO & President | 1960 |
| Gerald N. Herman CPA | Executive VP & CFO | 1959 |
| Mark R. Munch Ph.D. | Corporate Executive VP and President of Bruker Nano Group & Corporate | 1962 |
| Juergen W. Srega | President of Bruker CALID Group & Bruker Daltonics Division | 1955 |
| Falko Busse Ph.D. | President of Bruker BioSpin Group | 1967 |
| Thomas M. Bures | Chief Accounting Officer | 1975 |
| J. Brent Alldredge J.D. | Senior VP, General Counsel, Secretary & Global Head of Compliance | 1975 |
| Burkhard Prause Ph.D. | President and CEO of Bruker Energy & Supercon Technologies, Inc. | 1967 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Munch Mark | EXEC VP&PRES BRUKER NANO INC. | Sell | 2,000 | 60.25 | 120,500 |
| 15. Jul 2026 | Munch Mark | EXEC VP&PRES BRUKER NANO INC. | Other | 2,000 | 22.19 | 44,380 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.